Related Experiment Video
Updated: Jul 29, 2026
08:49
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Mental disorders in current and former heavy ecstasy (MDMA) users
R Thomasius1, K U Petersen, P Zapletalova
1Department of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf, Hamburg, Germany. thomasius@uke.uni-hamburg.de
Addiction (Abingdon, England)
|September 1, 2005
Summary
Ecstasy users did not show increased general psychopathology but frequently experienced substance-induced cognitive disorders. Long-term ecstasy use, measured in tablets, predicted these cognitive impairments, suggesting neurotoxic effects.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Psychology
Background:
- Ecstasy (MDMA) use is frequently linked to psychopathology, but prior research relied on subjective reports.
- Objective assessment of long-term mental health consequences in ecstasy users is crucial.
Purpose of the Study:
- To investigate long-term psychopathological outcomes in current and former ecstasy users.
- To determine if ecstasy use is associated with pre-existing mental health conditions.
Main Methods:
- Compared DSM-IV mental disorders in ecstasy users (current/former), polydrug users, and drug-naive controls.
- Matched groups by age, gender, and education; recorded lifetime ecstasy dosage.
- Assessed prevalence of substance-induced affective, anxiety, and cognitive disorders.
Main Results:
- Ecstasy users showed no increased general psychopathology compared to controls, except for substance use disorders.
- Substance-induced cognitive disorders were more prevalent in ecstasy users, even after prolonged abstinence.
- Lifetime ecstasy dose predicted current and lifetime cognitive disorders, indicating potential neurotoxicity.
Conclusions:
- Ecstasy use is unlikely motivated by self-medication of pre-existing depression or anxiety.
- Persistent cognitive disorders post-abstinence may result from MDMA's serotonergic neurotoxicity.
- Findings highlight the risk of long-term cognitive impairment from recreational ecstasy consumption.
Related Concept Videos
01:22CNS Stimulants: Psychedelic Agents
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
01:24Substance Use Disorders Affecting Sleep
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
01:27Hallucinogens and Psychedelics
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains delta-9-tetrahydrocannabinol (THC)...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains delta-9-tetrahydrocannabinol (THC)...
01:27Diagnostic and Statistical Manual of Mental Disorders (DSM)
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
01:27Depressive Disorders: MDD and Dysthymia
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...